Literature DB >> 14996642

Avinza - 24-h sustained-release oral morphine therapy.

Jacques R Caldwell1.   

Abstract

Avinza is a once-daily, extended-release oral morphine preparation. It has a pharmacokinetic profile that exhibits less peak-to-trough fluctuations in plasma concentration whilst providing analgesia statistically identical to that produced by MS Contin (controlled-release morphine sulfate), Oxycontin (oxycodone HCl controlled-release) and six doses of oral morphine sulfate administered every 4 h. Avinza improves quality of sleep by several measures but interestingly gives the best sleep improvement when given in the morning rather than at night. It causes the same side effects of other opioids: constipation, nausea, vomiting, somnolence and mood swings. Doses of 30 - 60 mg/day have been shown to be well tolerated by patients with osteoarthritis (even in the elderly), who have failed other medications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996642     DOI: 10.1517/14656566.5.2.469

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.

Authors:  Martin E Hale; Srinivas R Nalamachu; Arif Khan; Michael Kutch
Journal:  J Pain Res       Date:  2013-05-01       Impact factor: 3.133

Review 2.  Nanotherapeutic-directed approaches to analgesia.

Authors:  Liudmila L Mazaleuskaya; Vladimir R Muzykantov; Garret A FitzGerald
Journal:  Trends Pharmacol Sci       Date:  2021-04-19       Impact factor: 17.638

3.  Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.

Authors:  Elke Kleideiter; Chiara Piana; Shaonan Wang; Robert Nemeth; Michael Gautrois
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.